Cargando…

Gender Differences and Immunotherapy Outcome in Advanced Lung Cancer

In developed countries, lung cancer is the leading cause of cancer-related death in both sexes. Although cigarette smoking represents the principal risk factor for lung cancer in females, the higher proportion of this neoplasm among non-smoking women as compared with non-smoking men implies distinct...

Descripción completa

Detalles Bibliográficos
Autores principales: Vavalà, Tiziana, Catino, Annamaria, Pizzutilo, Pamela, Longo, Vito, Galetta, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584562/
https://www.ncbi.nlm.nih.gov/pubmed/34769372
http://dx.doi.org/10.3390/ijms222111942
_version_ 1784597479440777216
author Vavalà, Tiziana
Catino, Annamaria
Pizzutilo, Pamela
Longo, Vito
Galetta, Domenico
author_facet Vavalà, Tiziana
Catino, Annamaria
Pizzutilo, Pamela
Longo, Vito
Galetta, Domenico
author_sort Vavalà, Tiziana
collection PubMed
description In developed countries, lung cancer is the leading cause of cancer-related death in both sexes. Although cigarette smoking represents the principal risk factor for lung cancer in females, the higher proportion of this neoplasm among non-smoking women as compared with non-smoking men implies distinctive biological aspects between the two sexes. Gender differences depend not only on genetic, environmental, and hormonal factors but also on the immune system, and all these aspects are closely interconnected. In the last few years, it has been confirmed that the immune system plays a fundamental role in cancer evolution and response to oncological treatments, specifically immunotherapy, with documented distinctions between men and women. Consequently, in order to correctly assess cancer responses and disease control, considering only age and reproductive status, the results of studies conducted in female patients would probably not categorically apply to male patients and vice versa. The aim of this article is to review recent data about gender disparities in both healthy subjects’ immune system and lung cancer patients; furthermore, studies concerning gender differences in response to lung cancer immunotherapy are examined.
format Online
Article
Text
id pubmed-8584562
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85845622021-11-12 Gender Differences and Immunotherapy Outcome in Advanced Lung Cancer Vavalà, Tiziana Catino, Annamaria Pizzutilo, Pamela Longo, Vito Galetta, Domenico Int J Mol Sci Review In developed countries, lung cancer is the leading cause of cancer-related death in both sexes. Although cigarette smoking represents the principal risk factor for lung cancer in females, the higher proportion of this neoplasm among non-smoking women as compared with non-smoking men implies distinctive biological aspects between the two sexes. Gender differences depend not only on genetic, environmental, and hormonal factors but also on the immune system, and all these aspects are closely interconnected. In the last few years, it has been confirmed that the immune system plays a fundamental role in cancer evolution and response to oncological treatments, specifically immunotherapy, with documented distinctions between men and women. Consequently, in order to correctly assess cancer responses and disease control, considering only age and reproductive status, the results of studies conducted in female patients would probably not categorically apply to male patients and vice versa. The aim of this article is to review recent data about gender disparities in both healthy subjects’ immune system and lung cancer patients; furthermore, studies concerning gender differences in response to lung cancer immunotherapy are examined. MDPI 2021-11-04 /pmc/articles/PMC8584562/ /pubmed/34769372 http://dx.doi.org/10.3390/ijms222111942 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Vavalà, Tiziana
Catino, Annamaria
Pizzutilo, Pamela
Longo, Vito
Galetta, Domenico
Gender Differences and Immunotherapy Outcome in Advanced Lung Cancer
title Gender Differences and Immunotherapy Outcome in Advanced Lung Cancer
title_full Gender Differences and Immunotherapy Outcome in Advanced Lung Cancer
title_fullStr Gender Differences and Immunotherapy Outcome in Advanced Lung Cancer
title_full_unstemmed Gender Differences and Immunotherapy Outcome in Advanced Lung Cancer
title_short Gender Differences and Immunotherapy Outcome in Advanced Lung Cancer
title_sort gender differences and immunotherapy outcome in advanced lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584562/
https://www.ncbi.nlm.nih.gov/pubmed/34769372
http://dx.doi.org/10.3390/ijms222111942
work_keys_str_mv AT vavalatiziana genderdifferencesandimmunotherapyoutcomeinadvancedlungcancer
AT catinoannamaria genderdifferencesandimmunotherapyoutcomeinadvancedlungcancer
AT pizzutilopamela genderdifferencesandimmunotherapyoutcomeinadvancedlungcancer
AT longovito genderdifferencesandimmunotherapyoutcomeinadvancedlungcancer
AT galettadomenico genderdifferencesandimmunotherapyoutcomeinadvancedlungcancer